1 / 28

Established Prognostic Factors Associated With Inferior Survival

Established Prognostic Factors Associated With Inferior Survival. Advanced stage at diagnosis Short lymphocyte doubling time Diffuse pattern of bone marrow infiltration Advanced age/males Abnormal karyotype High serum levels of ß 2 -microglobulin. Summary: Prognostic Factors in CLL.

murray
Download Presentation

Established Prognostic Factors Associated With Inferior Survival

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Established Prognostic Factors Associated With Inferior Survival • Advanced stage at diagnosis • Short lymphocyte doubling time • Diffuse pattern of bone marrow infiltration • Advanced age/males • Abnormal karyotype • High serum levels of ß2-microglobulin

  2. Summary: Prognostic Factors in CLL • Various prognostic markers predict for disease progression and survival in CLL: • -2 microglobulin • IgVH gene mutation • CD38 • ZAP-70 • Current challenges • Defining and validating prognostic significance of markers • Identifying which are readily available and reliable • Addressing use in clinical management of patients

  3. Problems with Current Studies • “Uni-factorial” • Do not take into account the impact of other prognostic factors • Small patient numbers • Retrospective design • Selection bias • Survival from date of initial diagnosis, not date of test • Not uniformly treated

  4. Clonal Evolution by VH Mutation Status 100 % clonal evolution 80 Unmutated CLL 60 40 Mutated CLL 20 0 0 6 12 18 24 30 36 42 48 54 60 66 72 Time since initial genetic study (months)

  5. The MD Anderson Studies • CLL Database - prospective record of all patients assessed at MD Anderson. • Determinants of Survival • Progression to First Therapy • Complete Remission • Remission Duration } Untreated Patients N=594, 2003 - 2007 } FCR Study N=300, 1999 - 2003

  6. IgVH - Time to First TherapyInteraction with ß2m Unmutated IgVH Mutated IgVH ß2m < 3mg/L (n=160) p=NS ß2m ≥ 3mg/L (n=19) p=0.0005 ß2m < 3mg/L (n=89) ß2m ≥ 3mg/L (n=35)

  7. IgVH - Time to First TherapyInteraction with Genetic Status Deletion 13q / Negative FISH Trisomy 12 Mutated (n=152) Mutated (n=27) Unmutated (n=95) Unmutated (n=30) p<0.0001 p=NS

  8. Zeta-Associated Protein 70 (ZAP-70) Crespo et al 2003 348:1764 Rassenti et al 2004 351:893

  9. ZAP-70 by Immunohistochemistry Positive in CLL Infiltrate Negative in CLL Infiltrate Ellen Schlette, MD Hematopathology

  10. M, ZAP- (n=98) } p=NS M, ZAP+ (n=23) U, ZAP+ (n=74) } p=0.03 U, ZAP- (n=23) ZAP-70: Additional Value to IgVH? Time to First Therapy

  11. 100 80 60 40 20 0 0 12 24 36 48 60 72 84 96 108 120 132 144 156 168 180 Chromosome 17p Deletion (FISH) Dohner et al N Engl J Med. 343:1910-1916,2000 17p deletion 11q deletion 12q trisomy Normal 13q deletion as sole abnormality Patients Surviving (%) Months

  12. De Novo 17p- CLL : The MD Anderson Experience Not All Patients Progress…. Depending on Rai Stage & IgVH Status Rai 0, any IgVH (n=14) Rai 1-2, mutated (n=5) Rai 1-2, unmutated (n=11) p<0.0001 Lost 17p- clone on repeat FISH

  13. Determinants of Survival I : Biological Risk II : Symptoms Low Risk (23) Asymptomatic High Risk (13) High Risk (33) Symptomatic High Risk (20) p = 0.003 p = 0.04 Low Risk = Rai 0/1and <50% Deletion

  14. Deletion 17p CLL - Published Studies

  15. 100 <5% 75 Percent >20% 50 5-20% 25 2P < 0·00001 0 0 12 24 36 48 60 Months De Novo 17p- CLL: Survival GCLLSG-CLL4: F vs FC LRF-CLL4: Chl vs F vs FC (15) (18) (15) Stilgenbauer ASH 2005 Eichorst Blood 2006, 107: 885 Catovsky ASH 2004 Catovsky Lancet 2007, 370: 230

  16. The MD Anderson Experience (Dec 2003 - July 2007) Survival from FISH Date Survival from First Therapy N=56 N=38 80% at 24 months 75% at 24 months Follow-up 19 mth (5 - 47) Reasons : Early Stage Patients FISH Techniques Rituximab

  17. Fallacies in 17p- CLL Therapy 17p- ≥50% or DT <6M : 83% vs 26% Major Response (p=0.003)

  18. Frontline FCR in CLL: NCI Response (%) } Complete Response* 72 Nodular Partial Response 10 Partial Response 12 Stable / Progressive Disease 4 Early Death (3 months) <1 95 * 78% flow cytometry negative

  19. The FCR Study: IgVH Status Pre-treatment 79 patients Stored BM Clot Sections 98 patients Known : 177 of 300 pts Lin K, ASH 2007, Updated Feb 12th 2008

  20. Baseline Characteristics UM= Unmutated; M=Mutated; ND= Not determined *p=0.04

  21. The FCR Study : Response Rate *n=164

  22. The FCR Study : CR Duration & Survival Complete Remission Duration Overall Survival p<0.0001 p=0.05 Mutated (n=60) Mutated (n=72) Unmutated (n=77) Unmutated (n=105)

  23. ZAP-70: Additional Value to IgVH? CR Rate Following FCR FCR Remission Duration M, ZAP- (n=21) } p=NS ZAP+ ZAP- ZAP- ZAP+ M, ZAP+ (n=19) Unmutated Mutated U, ZAP+ (n=48) } p=0.26 U, ZAP- (n=13)

  24. Progression free Survival of FR and FCR by Mutation Status Mutation PFS Rx Status Pts Median (mo) %5 yr FR Unmutated 50 31 19 FR Mutated 38 46 40 FCR Unmutated 96 48 40 FCR Mutated 62 NR 75

  25. Frontline FCR in CLL: CR Duration p-value

  26. Multivariate Analysis of CR Duration p-value

  27. Conclusion III - 17p- / p53 *assumes that 17p- and p53 overexpression identifies the same group of patients

  28. Final Thoughts • CLL prognosis is multi-factorial: • Avoid interpretation of individual prognostic factors in isolation. • Therapeutic dissection: • Let the treatment outcome tell you what factors are truly important. • Only possible when patients are treated homogenously, with the best available therapy.

More Related